Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127174391 | 12717439 | 1 | I | 20160902 | 20160906 | 20160906 | EXP | GB-JNJFOC-20160904194 | JANSSEN | BANERJEE SN, OZA AM, HAMILTON EP, HASAN J, LEARY A, MOORE KN, ET AL. A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE (ADC) LIFASTUZUMAB (LIFA) VEDOTIN (DNIB0600A) COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS (PTS) WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC). JOURNAL OF CLINICAL ONCOLOGY 2016;34 (15):5569. | 0.00 | Y | 0.00000 | 20160906 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127174391 | 12717439 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | EVERY 4 WEEKS | U | 50718 | 40 | MG/M**2 | LIPOSOME INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127174391 | 12717439 | 1 | Ovarian cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127174391 | 12717439 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127174391 | 12717439 | Adverse event | |
| 127174391 | 12717439 | Neuropathy peripheral |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |